SG10201401305SA - Methods of predicting cancer risk using gene expression in premalignant tissue - Google Patents

Methods of predicting cancer risk using gene expression in premalignant tissue

Info

Publication number
SG10201401305SA
SG10201401305SA SG10201401305SA SG10201401305SA SG10201401305SA SG 10201401305S A SG10201401305S A SG 10201401305SA SG 10201401305S A SG10201401305S A SG 10201401305SA SG 10201401305S A SG10201401305S A SG 10201401305SA SG 10201401305S A SG10201401305S A SG 10201401305SA
Authority
SG
Singapore
Prior art keywords
methods
gene expression
cancer risk
predicting cancer
premalignant tissue
Prior art date
Application number
SG10201401305SA
Inventor
Wayne Cowens
Maureen T Cronin
Carl L Millward
François Collin
Michael Crager
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of SG10201401305SA publication Critical patent/SG10201401305SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG10201401305SA 2009-04-07 2010-04-07 Methods of predicting cancer risk using gene expression in premalignant tissue SG10201401305SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16750309P 2009-04-07 2009-04-07
US24370809P 2009-09-18 2009-09-18

Publications (1)

Publication Number Publication Date
SG10201401305SA true SG10201401305SA (en) 2014-08-28

Family

ID=42936861

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201401305SA SG10201401305SA (en) 2009-04-07 2010-04-07 Methods of predicting cancer risk using gene expression in premalignant tissue
SG2011070760A SG174611A1 (en) 2009-04-07 2010-04-07 Methods of predicting cancer risk using gene expression in premalignant tissue

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011070760A SG174611A1 (en) 2009-04-07 2010-04-07 Methods of predicting cancer risk using gene expression in premalignant tissue

Country Status (8)

Country Link
US (1) US8765383B2 (en)
EP (1) EP2417271A4 (en)
AU (1) AU2010234456A1 (en)
CA (1) CA2757927A1 (en)
IL (1) IL215253A0 (en)
NZ (1) NZ595356A (en)
SG (2) SG10201401305SA (en)
WO (1) WO2010118166A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974058B1 (en) * 2006-01-11 2014-06-11 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
SG175832A1 (en) * 2009-05-01 2011-12-29 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
EP3556870B9 (en) 2010-07-27 2022-09-28 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
AU2013207385B2 (en) * 2012-01-06 2018-09-13 Exact Sciences Corporation System and method of detecting RNAs altered by cancer in peripheral blood
MX351626B (en) 2012-01-31 2017-10-23 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer.
US9880156B2 (en) 2013-04-11 2018-01-30 Medite Cancer Diagnostics, Inc. Biological specimen evaluation methods using cytology and immunology
US20170067912A1 (en) * 2014-03-13 2017-03-09 The Penn State Research Foundation Compositions and methods for diagnosing barrett's esophagus stages
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
JP7065610B6 (en) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ Medical prognosis and prediction of therapeutic response using multiple cellular signaling pathway activities
JP7065609B6 (en) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ Medical prognosis and prediction of therapeutic response using multiple cellular signaling pathway activities
WO2016062891A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION
ITUB20150652A1 (en) 2015-05-21 2016-11-21 Univ Bologna Alma Mater Studiorum NEW DIAGNOSTIC METHOD AND KIT
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
ES2861400T3 (en) 2015-08-14 2021-10-06 Koninklijke Philips Nv Evaluation of the activity of the NFkB cell signaling pathway using mathematical models of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953658B2 (en) * 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US20040053317A1 (en) * 2002-09-10 2004-03-18 Sidney Kimmel Cancer Center Gene segregation and biological sample classification methods
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE520979T1 (en) 2005-08-24 2011-09-15 Bristol Myers Squibb Co BIOMARRKERS AND METHODS FOR DETERMINING SENSITIVITY TO MODULATORS OF THE EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR
EP1974058B1 (en) 2006-01-11 2014-06-11 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
US7812143B2 (en) * 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
NZ589143A (en) * 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
WO2010033371A2 (en) * 2008-09-22 2010-03-25 Advpharma, Inc. Molecular markers for lung and colorectal carcinomas

Also Published As

Publication number Publication date
US20100291573A1 (en) 2010-11-18
EP2417271A2 (en) 2012-02-15
US8765383B2 (en) 2014-07-01
AU2010234456A1 (en) 2011-10-20
EP2417271A4 (en) 2012-08-29
SG174611A1 (en) 2011-11-28
CA2757927A1 (en) 2010-10-14
NZ595356A (en) 2013-07-26
IL215253A0 (en) 2011-12-29
WO2010118166A2 (en) 2010-10-14
WO2010118166A3 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
IL215253A0 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
IL276487B (en) Methods to predict clinical outcome of cancer
IL280689B (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2401357A4 (en) Host cells and methods of use
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
IL218575A0 (en) Treatment of cancer
HK1217763A1 (en) Methods of treating diseases
IL216044A0 (en) Method of expanding human hepatocytes in vivo
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
EP2438197A4 (en) Methods of detecting cancer
EP2389573A4 (en) Skin analysis methods
EP2373794A4 (en) Nectin-4 for target genes of cancer therapy and diagnosis
EP2398901A4 (en) Jarid1b for target gene of cancer therapy and diagnosis
EP2475790A4 (en) Methods and compositions for predicting cancer therapy response
EP2467140A4 (en) Method of threating cancer
EP2402053A4 (en) Electrohydraulic prostate tissue treatment probe
GB0908788D0 (en) Tissue analysis
EP2470903A4 (en) Gene and polypeptide relating to breast cancer
EP2384370A4 (en) Use of id4 for diagnosis and treatment of cancer
GB0916686D0 (en) Treatment of cancer
EP2350276A4 (en) Syngr4 for target genes of cancer therapy and diagnosis
EP2262541A4 (en) C2orf18 as target gene for cancer therapy and diagnosis
TWM371583U (en) Mashing structure of anvil block
GB0921757D0 (en) Treatment of cancer
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer